{"id":411,"date":"2026-09-23T07:10:10","date_gmt":"2026-09-23T07:10:10","guid":{"rendered":"https:\/\/noimfine.com\/sph06\/?p=411"},"modified":"2026-09-23T07:10:10","modified_gmt":"2026-09-23T07:10:10","slug":"fda-approves-uplizna-a-twice-yearly-targeted-therapy-for-adults-with-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/noimfine.com\/sph06\/2026\/09\/23\/fda-approves-uplizna-a-twice-yearly-targeted-therapy-for-adults-with-generalized-myasthenia-gravis\/","title":{"rendered":"FDA Approves Uplizna: A Twice-Yearly Targeted Therapy for Adults With Generalized Myasthenia Gravis"},"content":{"rendered":"
<\/p>\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
Uplizna<\/a> (inebilizumab-cdon) is a prescription medicine recently approved by the FDA to treat adults with generalized myasthenia gravis (gMG) who test positive for certain antibodies \u2014 either anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibodies. The approval provides a new treatment that may help control the disease long term with just two doses per year through an intravenous (IV) infusion after two initial loading doses.<\/p>\n

gMG is a long-term autoimmune condition that disrupts how nerves and muscles communicate, leading to muscle weakness that comes and goes and can make walking, talking, swallowing, or breathing harder. The disease is caused by the immune system producing specific antibodies (anti-AChR and anti-MuSK autoantibodies) that attack the connections between nerves and muscles. About 80,000 to 100,000 people in the U.S. live with MG, and most of them (about 85%) have the generalized form.<\/p>\n

Uplizna is a monoclonal antibody that works by targeting and removing certain immune cells known as CD19-positive B cells that produce the harmful antibodies responsible for the condition. By removing these cells, this medicine may help reduce symptoms and prevent flare-ups. First approved in 2020, Uplizna is also used to treat other rare autoimmune diseases in adults, including neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease.<\/p>\n

What makes Uplizna different is that it\u2019s the first FDA-approved treatment for gMG that specifically targets CD19-positive B cells. It requires less frequent dosing, which may be more convenient than other therapies that require regular administration.<\/p>\n<\/section>\n<\/div>\n

\n
\n

Why Was It Approved?<\/h2>\n

Uplizna was approved based on results from a large clinical study that included adults with gMG who tested positive for either anti-AChR or anti-MuSK antibodies. In the study, people who received Uplizna had better muscle strength and improved daily function compared with those who received a placebo.<\/p>\n

The trial included 238 adults with gMG, including both AChR+ (190) and MuSK+ (48) patients. Patients on steroids at baseline started reducing the dose at week 4, aiming for a specific low dose by week 24. By week 26, 87% of patients taking Uplizna and 85% of patients taking placebo reached this low steroid dose. At the same time, Uplizna improved daily living activities, with patients showing a 1.9-point greater improvement (-4.2 vs -2.2) on a predefined scoring system (the MG-ADL score) than those taking placebo; AChR+ patients continued to benefit through week 52 with a 2.8-point improvement (-4.7 vs -1.9). Uplizna also reduced muscle weakness as measured by the Quantitative Myasthenia Gravis score (-4.8 vs -2.3).<\/p>\n<\/section>\n

The most common side effects are headache, cough, mild infections, and infusion reactions, with no increase in the incidence of serious side effects.<\/p>\n

More serious risks include the return of hepatitis B virus (HBV) infection and a rare brain infection called progressive multifocal leukoencephalopathy (PML), although no cases of PML were reported in the study. Because of these risks, people with active HBV infection or tuberculosis were not included in the study.<\/p>\n<\/section>\n

\n

What Do I Need to Know?<\/h2>\n

Uplizna is given through an IV infusion. You\u2019ll get two starting doses two weeks apart, followed by one dose every six months. Each infusion takes about 90 minutes, and your health care provider will monitor you for at least an hour afterward to check for any side effects.<\/p>\n

Before each infusion, you\u2019ll receive medicines like steroids, antihistamines, and fever reducers to help lower the chance of infusion-related reactions. Some people may also get infections like urinary tract infections or colds.<\/p>\n

Be sure to tell your health care provider about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal or natural supplements, especially those that affect your immune system.<\/p>\n<\/section>\n<\/div>\n

\n
You\u2019ll need to be screened for infections like HBV infection and tuberculosis before starting treatment. Any live or live-attenuated vaccines should be given at least four weeks before your first dose. These vaccines aren\u2019t recommended while you\u2019re on Uplizna or until your immune system recovers.<\/p>\n

Infants exposed to Uplizna during pregnancy should not receive live or live-attenuated vaccines until their B-cell counts have recovered as low B-cell counts may increase the risk for infection. Non-live vaccines can be given, but a specialist should check whether the baby\u2019s immune system can respond properly.<\/p>\n

Uplizna should not be used if you have an active HBV infection, untreated or active tuberculosis, or if you\u2019ve had a life-threatening reaction to the medicine in the past. If you can become pregnant, you\u2019ll need to use birth control during treatment and for six months after your last dose as this medicine may harm a fetus.<\/p>\n<\/section>\n<\/div>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Uplizna (inebilizumab-cdon) is a prescription medicine recently approved by the FDA to treat adults with generalized myasthenia gravis (gMG) who test positive for certain antibodies \u2014 either anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibodies. The approval provides… <\/p>\n","protected":false},"author":2,"featured_media":413,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-spot"],"_links":{"self":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/comments?post=411"}],"version-history":[{"count":1,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/411\/revisions"}],"predecessor-version":[{"id":414,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/411\/revisions\/414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media\/413"}],"wp:attachment":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media?parent=411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/categories?post=411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/tags?post=411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}